Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Frontiers in Immunology
|
August 4, 2022
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS
Margherita Bellucci, Francesco Germano, Stefano Grisanti, et al.
Scientific Reports
|
August 12, 2017
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies
Giovanna Capodivento, Davide Visigalli, Martina Garnero, et al.
Frontiers in Neurology
|
September 28, 2020
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A
Davide Visigalli, Giovanna Capodivento, Abdul Basit, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 23, 2020
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
Giovanna Capodivento, Chiara De Michelis, Marinella Carpo, et al.
Biomarker Insights
|
July 8, 2025
A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker
Giovanna Capodivento, Davide Visigalli, Andrea Armirotti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
January 3, 2024
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome
Federico Massa, Tiziana Vigo, Margherita Bellucci, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Frontiers in Immunology
|
August 4, 2022
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS
Margherita Bellucci, Francesco Germano, Stefano Grisanti, et al.
Scientific Reports
|
August 12, 2017
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies
Giovanna Capodivento, Davide Visigalli, Martina Garnero, et al.
Frontiers in Neurology
|
September 28, 2020
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A
Davide Visigalli, Giovanna Capodivento, Abdul Basit, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 23, 2020
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
Giovanna Capodivento, Chiara De Michelis, Marinella Carpo, et al.
Biomarker Insights
|
July 8, 2025
A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker
Giovanna Capodivento, Davide Visigalli, Andrea Armirotti, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
January 3, 2024
COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome
Federico Massa, Tiziana Vigo, Margherita Bellucci, et al.
Page
of 2